{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T08:06:44Z","timestamp":1793434004005,"version":"4.5.0"},"reference-count":54,"publisher":"American Association for Cancer Research (AACR)","issue":"8","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>We evaluated the safety and activity of autologous T cells expressing NY-ESO-1c259, an affinity-enhanced T-cell receptor (TCR) recognizing an HLA-A2\u2013restricted NY-ESO-1\/LAGE1a\u2013derived peptide, in patients with metastatic synovial sarcoma (NY-ESO-1c259T cells). Confirmed antitumor responses occurred in 50% of patients (6\/12) and were characterized by tumor shrinkage over several months. Circulating NY-ESO-1c259T cells were present postinfusion in all patients and persisted for at least 6 months in all responders. Most of the infused NY-ESO-1c259T cells exhibited an effector memory phenotype following ex vivo expansion, but the persisting pools comprised largely central memory and stem-cell memory subsets, which remained polyfunctional and showed no evidence of T-cell exhaustion despite persistent tumor burdens. Next-generation sequencing of endogenous TCRs in CD8+ NY-ESO-1c259T cells revealed clonal diversity without contraction over time. These data suggest that regenerative pools of NY-ESO-1c259T cells produced a continuing supply of effector cells to mediate sustained, clinically meaningful antitumor effects.<\/jats:p>\n                  <jats:p>Significance: Metastatic synovial sarcoma is incurable with standard therapy. We employed engineered T cells targeting NY-ESO-1, and the data suggest that robust, self-regenerating pools of CD8+ NY-ESO-1c259T cells produce a continuing supply of effector cells over several months that mediate clinically meaningful antitumor effects despite prolonged exposure to antigen. Cancer Discov; 8(8); 944\u201357. \u00a92018 AACR.<\/jats:p>\n                  <jats:p>See related commentary by Keung and Tawbi, p. 914.<\/jats:p>\n                  <jats:p>This article is highlighted in the In This Issue feature, p. 899<\/jats:p>","DOI":"10.1158\/2159-8290.cd-17-1417","type":"journal-article","created":{"date-parts":[[2018,6,11]],"date-time":"2018-06-11T03:25:20Z","timestamp":1528687520000},"page":"944-957","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":420,"title":["Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1 c259T Cells in Synovial Sarcoma"],"prefix":"10.1158","volume":"8","author":[{"given":"Sandra P.","family":"D'Angelo","sequence":"first","affiliation":[{"name":"1Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Melchiori","sequence":"additional","affiliation":[{"name":"2Adaptimmune, Oxford, United Kingdom, and Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melinda S.","family":"Merchant","sequence":"additional","affiliation":[{"name":"3Pediatric Oncology Branch, NCI, Bethesda, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna","family":"Bernstein","sequence":"additional","affiliation":[{"name":"3Pediatric Oncology Branch, NCI, Bethesda, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Glod","sequence":"additional","affiliation":[{"name":"3Pediatric Oncology Branch, NCI, Bethesda, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosandra","family":"Kaplan","sequence":"additional","affiliation":[{"name":"3Pediatric Oncology Branch, NCI, Bethesda, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Grupp","sequence":"additional","affiliation":[{"name":"4Children's Hospital of Philadelphia, Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William D.","family":"Tap","sequence":"additional","affiliation":[{"name":"1Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Chagin","sequence":"additional","affiliation":[{"name":"2Adaptimmune, Oxford, United Kingdom, and Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gwendolyn K.","family":"Binder","sequence":"additional","affiliation":[{"name":"2Adaptimmune, Oxford, United Kingdom, and Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samik","family":"Basu","sequence":"additional","affiliation":[{"name":"2Adaptimmune, Oxford, United Kingdom, and Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel E.","family":"Lowther","sequence":"additional","affiliation":[{"name":"2Adaptimmune, Oxford, United Kingdom, and Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruoxi","family":"Wang","sequence":"additional","affiliation":[{"name":"2Adaptimmune, Oxford, United Kingdom, and Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Bath","sequence":"additional","affiliation":[{"name":"2Adaptimmune, Oxford, United Kingdom, and Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Tipping","sequence":"additional","affiliation":[{"name":"2Adaptimmune, Oxford, United Kingdom, and Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gareth","family":"Betts","sequence":"additional","affiliation":[{"name":"2Adaptimmune, Oxford, United Kingdom, and Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Indu","family":"Ramachandran","sequence":"additional","affiliation":[{"name":"2Adaptimmune, Oxford, United Kingdom, and Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Marc","family":"Navenot","sequence":"additional","affiliation":[{"name":"2Adaptimmune, Oxford, United Kingdom, and Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Zhang","sequence":"additional","affiliation":[{"name":"3Pediatric Oncology Branch, NCI, Bethesda, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel K.","family":"Wells","sequence":"additional","affiliation":[{"name":"5Parker Institute for Cancer Immunotherapy, San Francisco, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Van Winkle","sequence":"additional","affiliation":[{"name":"2Adaptimmune, Oxford, United Kingdom, and Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabor","family":"Kari","sequence":"additional","affiliation":[{"name":"2Adaptimmune, Oxford, United Kingdom, and Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trupti","family":"Trivedi","sequence":"additional","affiliation":[{"name":"2Adaptimmune, Oxford, United Kingdom, and Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Holdich","sequence":"additional","affiliation":[{"name":"2Adaptimmune, Oxford, United Kingdom, and Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lini","family":"Pandite","sequence":"additional","affiliation":[{"name":"2Adaptimmune, Oxford, United Kingdom, and Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Amado","sequence":"additional","affiliation":[{"name":"2Adaptimmune, Oxford, United Kingdom, and Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0359-9023","authenticated-orcid":false,"given":"Crystal L.","family":"Mackall","sequence":"additional","affiliation":[{"name":"3Pediatric Oncology Branch, NCI, Bethesda, Maryland."},{"name":"5Parker Institute for Cancer Immunotherapy, San Francisco, California."},{"name":"6Stanford University, Stanford, California."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2018,8,2]]},"reference":[{"key":"2022060701200428800_bib1","volume-title":"Management of soft tissue sarcoma","author":"Brennan","year":"2012"},{"key":"2022060701200428800_bib2","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"2022060701200428800_bib3","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N Engl J Med"},{"key":"2022060701200428800_bib4","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl J Med"},{"key":"2022060701200428800_bib5","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/nature13904","article-title":"MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer","volume":"515","author":"Powles","year":"2014","journal-title":"Nature"},{"key":"2022060701200428800_bib6","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","article-title":"Immune checkpoint blockade: a common denominator approach to cancer therapy","volume":"27","author":"Topalian","year":"2015","journal-title":"Cancer Cell"},{"key":"2022060701200428800_bib7","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"key":"2022060701200428800_bib8","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1126\/science.aaa4971","article-title":"Neoantigens in cancer immunotherapy","volume":"348","author":"Schumacher","year":"2015","journal-title":"Science"},{"key":"2022060701200428800_bib9","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1126\/science.aaf1490","article-title":"Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade","volume":"351","author":"McGranahan","year":"2016","journal-title":"Science"},{"key":"2022060701200428800_bib10","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Cancer immunology. mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"key":"2022060701200428800_bib11","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med"},{"key":"2022060701200428800_bib12","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nature12477","article-title":"Signatures of mutational processes in human cancer","volume":"500","author":"Alexandrov","year":"2013","journal-title":"Nature"},{"key":"2022060701200428800_bib13","first-page":"33","article-title":"SARC 028: a phase II study of the anti-PD1 antibody pembrolizumab (P) in patients (Pts) with advanced sarcomas","author":"Burgess","year":"2015","journal-title":"J Clin Oncol"},{"key":"2022060701200428800_bib14","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1002\/ijc.1282","article-title":"Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues","volume":"92","author":"Jungbluth","year":"2001","journal-title":"Int J Cancer"},{"key":"2022060701200428800_bib15","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1097\/01.LAB.0000017169.26718.5F","article-title":"The cancer-testis gene, NY-ESO-1, is expressed in normal fetal and adult testes and in spermatocytic seminomas and testicular carcinoma in situ","volume":"82","author":"Satie","year":"2002","journal-title":"Lab Invest"},{"key":"2022060701200428800_bib16","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1038\/modpathol.2012.31","article-title":"NY-ESO-1 expression in synovial sarcoma and other mesenchymal tumors: significance for NY-ESO-1-based targeted therapy and differential diagnosis","volume":"25","author":"Lai","year":"2012","journal-title":"Mod Pathol"},{"key":"2022060701200428800_bib17","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1002\/ijc.26074","article-title":"Heteroclitic serological response in esophageal and prostate cancer patients after NY-ESO-1 protein vaccination","volume":"130","author":"Kawada","year":"2012","journal-title":"Int J Cancer"},{"key":"2022060701200428800_bib18","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/ijc.27682","article-title":"Induction of CD8 T-cell responses restricted to multiple HLA class I alleles in a cancer patient by immunization with a 20-mer NY-ESO-1f (NY-ESO-1 91-110) peptide","volume":"132","author":"Eikawa","year":"2013","journal-title":"Int J Cancer"},{"key":"2022060701200428800_bib19","doi-asserted-by":"crossref","DOI":"10.1097\/CJI.0000000000000162","article-title":"NY-ESO-1 protein cancer vaccine with poly-ICLC and OK-432: rapid and strong induction of NY-ESO-1-specific immune responses by poly-ICLC","author":"Takeoka","year":"2017  23","journal-title":"J Immunother"},{"key":"2022060701200428800_bib20","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1002\/ijc.25955","article-title":"A phase I study of vaccination with NY-ESO-1f peptide mixed with Picibanil OK-432 and Montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen","volume":"129","author":"Kakimi","year":"2011","journal-title":"Int J Cancer"},{"key":"2022060701200428800_bib21","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1097\/CJI.0000000000000017","article-title":"Vaccination with NY-ESO-1 overlapping peptides mixed with Picibanil OK-432 and montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen","volume":"37","author":"Wada","year":"2014","journal-title":"J Immunother"},{"key":"2022060701200428800_bib22","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1158\/1078-0432.CCR-14-2708","article-title":"A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response","volume":"21","author":"Robbins","year":"2015","journal-title":"Clin Cancer Res"},{"key":"2022060701200428800_bib23","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1200\/JCO.2010.32.2537","article-title":"Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1","volume":"29","author":"Robbins","year":"2011","journal-title":"J Clin Oncol"},{"key":"2022060701200428800_bib24","doi-asserted-by":"crossref","first-page":"4564","DOI":"10.1002\/cncr.27446","article-title":"NY-ESO-1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid\/round cell liposarcoma","volume":"118","author":"Pollack","year":"2012","journal-title":"Cancer"},{"key":"2022060701200428800_bib25","doi-asserted-by":"crossref","first-page":"5845","DOI":"10.4049\/jimmunol.179.9.5845","article-title":"High-affinity TCRs generated by phage display provide CD4+ T cells with the ability to recognize and kill tumor cell lines","volume":"179","author":"Zhao","year":"2007","journal-title":"J Immunol"},{"key":"2022060701200428800_bib26","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1182\/blood-2015-03-631853","article-title":"CMV reactivation drives posttransplant T-cell reconstitution and results in defects in the underlying TCRbeta repertoire","volume":"125","author":"Suessmuth","year":"2015","journal-title":"Blood"},{"key":"2022060701200428800_bib27","doi-asserted-by":"crossref","first-page":"224ra25","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci Transl Med"},{"key":"2022060701200428800_bib28","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"key":"2022060701200428800_bib29","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"key":"2022060701200428800_bib30","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1200\/JCO.2014.56.2025","article-title":"Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor","volume":"33","author":"Kochenderfer","year":"2015","journal-title":"J Clin Oncol"},{"key":"2022060701200428800_bib31","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J Clin Invest"},{"key":"2022060701200428800_bib32","doi-asserted-by":"crossref","first-page":"355ra116","DOI":"10.1126\/scitranslmed.aaf8621","article-title":"Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells","volume":"8","author":"Turtle","year":"2016","journal-title":"Sci Transl Med"},{"key":"2022060701200428800_bib33","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1200\/JCO.2014.58.9093","article-title":"Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells","volume":"33","author":"Stevanovic","year":"2015","journal-title":"J Clin Oncol"},{"key":"2022060701200428800_bib34","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1126\/science.1251102","article-title":"Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer","volume":"344","author":"Tran","year":"2014","journal-title":"Science"},{"key":"2022060701200428800_bib35","doi-asserted-by":"crossref","first-page":"3174","DOI":"10.1002\/eji.201242606","article-title":"Different affinity windows for virus and cancer-specific T-cell receptors: implications for therapeutic strategies","volume":"42","author":"Aleksic","year":"2012","journal-title":"Eur J Immunol"},{"key":"2022060701200428800_bib36","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/nm.3910","article-title":"NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma","volume":"21","author":"Rapoport","year":"2015","journal-title":"Nat Med"},{"key":"2022060701200428800_bib37","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1038\/nm.2446","article-title":"A human memory T cell subset with stem cell-like properties","volume":"17","author":"Gattinoni","year":"2011","journal-title":"Nat Med"},{"key":"2022060701200428800_bib38","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nrc3322","article-title":"Paths to stemness: building the ultimate antitumour T cell","volume":"12","author":"Gattinoni","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"2022060701200428800_bib39","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1084\/jem.20091175","article-title":"One naive T cell, multiple fates in CD8+ T cell differentiation","volume":"207","author":"Gerlach","year":"2010","journal-title":"J Exp Med"},{"key":"2022060701200428800_bib40","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1749-6632.2010.05830.x","article-title":"The descent of memory T cells","volume":"1217","author":"Gerlach","year":"2011","journal-title":"Ann N Y Acad Sci"},{"key":"2022060701200428800_bib41","doi-asserted-by":"crossref","first-page":"9571","DOI":"10.1073\/pnas.0503726102","article-title":"Central memory self\/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells","volume":"102","author":"Klebanoff","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022060701200428800_bib42","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1172\/JCI24480","article-title":"Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells","volume":"115","author":"Gattinoni","year":"2005","journal-title":"J Clin Invest"},{"key":"2022060701200428800_bib43","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.1182\/blood-2013-06-506741","article-title":"Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study","volume":"122","author":"Cruz","year":"2013","journal-title":"Blood"},{"key":"2022060701200428800_bib44","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1038\/leu.2017.39","article-title":"Vaccination to improve the persistence of CD19CAR gene-modified T cells in relapsed pediatric acute lymphoblastic leukemia","volume":"31","author":"Rossig","year":"2017","journal-title":"Leukemia"},{"key":"2022060701200428800_bib45","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.jcyt.2013.10.013","article-title":"Relation of clinical culture method to T-cell memory status and efficacy in xenograft models of adoptive immunotherapy","volume":"16","author":"Barrett","year":"2014","journal-title":"Cytotherapy"},{"key":"2022060701200428800_bib46","doi-asserted-by":"crossref","first-page":"303ra139","DOI":"10.1126\/scitranslmed.aac5415","article-title":"Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia","volume":"7","author":"Porter","year":"2015","journal-title":"Sci Transl Med"},{"key":"2022060701200428800_bib47","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1089\/scd.1.1998.7.437","article-title":"Large-scale production of CD4+ T cells from HIV-1-infected donors after CD3\/CD28 costimulation","volume":"7","author":"Levine","year":"1998","journal-title":"J Hematother"},{"key":"2022060701200428800_bib48","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/1074-7613(95)90161-2","article-title":"CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-xL","volume":"3","author":"Boise","year":"1995","journal-title":"Immunity"},{"key":"2022060701200428800_bib49","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/S1074-7613(02)00323-0","article-title":"The CD28 signaling pathway regulates glucose metabolism","volume":"16","author":"Frauwirth","year":"2002","journal-title":"Immunity"},{"key":"2022060701200428800_bib50","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1084\/jem.183.6.2471","article-title":"Regulated expression of telomerase activity in human T lymphocyte development and activation","volume":"183","author":"Weng","year":"1996","journal-title":"J Exp Med"},{"key":"2022060701200428800_bib51","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.immuni.2009.09.007","article-title":"\u201cMIATA\u201d-minimal information about T cell assays","volume":"31","author":"Janetzki","year":"2009","journal-title":"Immunity"},{"key":"2022060701200428800_bib52","volume-title":"R: a language and environment for statistical computing","author":"R Developmental Core Team","year":"2010"},{"key":"2022060701200428800_bib53","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1007\/s00262-012-1384-4","article-title":"Bi-specific TCR-anti CD3 redirected T-cell targeting of NY-ESO-1- and LAGE-1-positive tumors","volume":"62","author":"McCormack","year":"2013","journal-title":"Cancer Immunol Immunother"},{"key":"2022060701200428800_bib54","doi-asserted-by":"crossref","first-page":"197ra03","DOI":"10.1126\/scitranslmed.3006034","article-title":"Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells","volume":"5","author":"Cameron","year":"2013","journal-title":"Sci Transl Med"}],"container-title":["Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/8\/8\/944\/1840947\/944.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/8\/8\/944\/1840947\/944.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,6]],"date-time":"2022-06-06T21:20:35Z","timestamp":1654550435000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article\/8\/8\/944\/10003\/Antitumor-Activity-Associated-with-Prolonged"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,1]]},"references-count":54,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2018,8,2]]},"published-print":{"date-parts":[[2018,8,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2159-8290.cd-17-1417","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/2159-8290.c.6546836.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.c.6546836","asserted-by":"object"}],"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2159-8290.22532801","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22532801.v1","asserted-by":"object"}]},"ISSN":["2159-8274","2159-8290"],"issn-type":[{"value":"2159-8274","type":"print"},{"value":"2159-8290","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,1]]}}}